KCA
Search
- Page Path
- HOME > Search
Original Article
- Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing
- Eunhyang Park, Hyo Sup Shim
- Cancer Res Treat. 2020;52(2):543-551. Published online November 8, 2019
- DOI: https://doi.org/10.4143/crt.2019.305
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) are ‘must-test’ biomarkers in the molecular diagnostics of advanced-stage lung cancer patients. Although single-gene assays are currently considered the gold standard for these genes, next-generation sequencing (NGS) tests are being introduced to clinical practices. We compared the results of current diagnostics and aimed to suggest timely effective guidance for their clinical use.
Materials and Methods
Patients with lung cancer who received both conventional single-gene assays and subsequent targeted NGS testing were enrolled, and the results of their tests were compared.
Results
A total of 241 patients were enrolled, and the EGFR real-time polymerase chain reaction, ALK fluorescence in situ hybridization (FISH), and ROS1 FISH assays exhibited 92.9%, 99.6%, and 99.5% concordance with the NGS tests, respectively. The discordant cases were mostly false-negatives of the single-gene assays, probably due to technical limitation. Of 158 cases previously designated as wild-type, EGFR, ALK, and ROS1 alterations were identified in 10.1%, 1.9%, and 1.3%, respectively, and other targetable alterations were identified in 36.1% of the cases. Of patients with additionally identified actionable alterations, 32.6% (31/95) received matched therapy with a clinical benefit of 48.4% (15/31).
Conclusion
Even though the conventional and NGS methods were concordant in the majority of cases, NGS testing still revealed a considerable number of additional EGFR, ALK, and ROS1 alterations, as well as other targetable alterations, in Korean advanced-stage lung cancer patients. Given the high frequency of EGFR and other targetable mutations identified in the present study, NGS testing is highly recommended in the diagnosis of Korean lung cancer patients. -
Citations
Citations to this article as recorded by
- Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma
Jae Seok Lee, Eun Kyung Kim, Kyung A Kim, Hyo Sup Shim
Cancer Research and Treatment.2024; 56(1): 104. CrossRef - Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis
Jiamin Lu, Yuqian Feng, Kaibo Guo, Leitao Sun, Shanming Ruan, Kai Zhang
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef - Cost-effectiveness of next-generation sequencing for advanced EGFR/ALK-negative non-small cell lung cancer
Dong-Won Kang, Sun-Kyeong Park, Sokbom Kang, Eui-Kyung Lee
Lung Cancer.2024; 197: 107970. CrossRef - Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system
Ching-Yao Yang, Jin-Yuan Shih, Wei-Yu Liao, Chao-Chi Ho, Chia-Lin Hsu, Tzu-Hsiu Tsai, Shang-Gin Wu, Yen-Ting Lin, Wei-Hsun Hsu, Suyog Jain, Steve Olsen, James Chih-Hsin Yang, Chong-Jen Yu, Pan-Chyr Yang
European Journal of Cancer.2023; 193: 113310. CrossRef - Clinicopathological Characteristics of NRG1 Fusion–Positive Solid Tumors in Korean Patients
Yoon Jin Cha, Chung Lee, Bio Joo, Kyung A Kim, Choong-kun Lee, Hyo Sup Shim
Cancer Research and Treatment.2023; 55(4): 1087. CrossRef - Differences in genomic profile of high-grade urothelial carcinoma according to tumor location
Cheol Keun Park, Nam Hoon Cho
Urologic Oncology: Seminars and Original Investigations.2022; 40(3): 109.e1. CrossRef - Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations
Yoon Ji Choi, Jung Yoon Choi, Ju Won Kim, Ah Reum Lim, Youngwoo Lee, Won Jin Chang, Soohyeon Lee, Jae Sook Sung, Hee-Joon Chung, Jong Won Lee, Eun Joo Kang, Jung Sun Kim, Taekyu Lim, Hye Sook Kim, Yu Jung Kim, Mi Sun Ahn, Young Saing Kim, Ji Hyun Park, Se
Cancer Research and Treatment.2022; 54(1): 30. CrossRef - Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations
Kyung Hwan Kim, Han Sang Kim, Seung-seob Kim, Hyo Sup Shim, Andrew Jihoon Yang, Jason Joon Bock Lee, Hong In Yoon, Joong Bae Ahn, Jee Suk Chang
Cancer Research and Treatment.2022; 54(1): 54. CrossRef - Utility of Single-Gene Testing in Cancer Specimens
Mehenaz Hanbazazh, Diana Morlote, Alexander C. Mackinnon, Shuko Harada
Clinics in Laboratory Medicine.2022; 42(3): 385. CrossRef - Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
Journal of Pathology and Translational Medicine.2022; 56(5): 249. CrossRef - Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy
Jii Bum Lee, Hyung Soon Park, Su Jin Choi, Seong Gu Heo, Ho Jung An, Hye Ryun Kim, Min Hee Hong, Sun Min Lim, Kyle Chang, Katie Quinn, Justin Odegaard, Byoung Yong Shim, Byoung Chul Cho
Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef - Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation
Jisheng Li, Liping Zhu, Justin Stebbing, Ling Peng
Journal of Cancer Research and Therapeutics.2022; 18(5): 1436. CrossRef - Lung cancer pathogenesis and poor response to therapy were dependent on driver oncogenic mutations
Xin Sun, Kai Li, Rui Zhao, Ye Sun, Jie Xu, Zi-Yang Peng, Run-Dong Song, Hong Ren, Shou-Ching Tang
Life Sciences.2021; 265: 118797. CrossRef - Patient-Specific Multi-Omics Models and the Application in Personalized Combination Therapy
August John, Bo Qin, Krishna R Kalari, Liewei Wang, Jia Yu
Future Oncology.2020; 16(23): 1737. CrossRef - Genetic Markers in Lung Cancer Diagnosis: A Review
Katarzyna Wadowska, Iwona Bil-Lula, Łukasz Trembecki, Mariola Śliwińska-Mossoń
International Journal of Molecular Sciences.2020; 21(13): 4569. CrossRef
- Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma
- 8,415 View
- 266 Download
- 16 Web of Science
- 15 Crossref
First
Prev
